Skip to main content

BAP Pharma

Insights

Find the latest updates, news and insights from across BAP Pharma’s expert teams.

September 18, 2026
Download the full guide For families, caregivers and healthcare professionals looking to understand Early Access Programs in more detail, the full guide...
August 6, 2026
From the outside, a Managed Access Program can look deceptively simple. A patient needs treatment. A physician makes a request. Medicine is...
July 20, 2026
For years, Rare Disease Access has been defined by three critical questions: Does a treatment exist? Is it approved? Will it be...
July 20, 2026
Across the life sciences industry, there is growing pressure to accelerate the path from development to patient access. Faster IND approvals, streamlined...
May 6, 2026
The Ehlers-Danlos Society – Why are people with EDS and HSD receiving such late access to innovative therapies?  What is Ehlers-Danlos syndrome...
March 12, 2026
Managed Access Programs are a key pillar of the drug development lifecycle, yet they remain widely misunderstood – both by the people...
February 13, 2026
How we help Biotechs save lives sooner  Patients with rare diseases face all kinds of challenges in their lives, including accessing the...
July 21, 2025
How It Started One of our key focuses at BAP Pharma is to actively engage with patient advocacy groups (PAGs), particularly in...
May 20, 2025
Early Access Programs (EAPs) offer a critical pathway for patients with serious or life-threatening conditions to access potentially life-saving treatments before they...